Abstract:The immune system can suppress tumour development both by eliminating malignant cells and by preventing the outgrowth and spread of cancer cells that resist eradication1. Clinical and experimental data suggest that the latter mode of control—termed cancer–immune equilibrium1—can be maintained for prolonged periods of time, possibly up to several decades2–4. Although cancers most frequently originate in epithelial layers, the nature and spatiotemporal dynamics of immune responses that maintain cancer–immune equilibrium in these tissue compartments remain unclear. Here, using a mouse model of transplantable cutaneous melanoma5, we show that tissue-resident memory CD8+ T cells (TRM cells) promote a durable melanoma–immune equilibrium that is confined to the epidermal layer of the skin. A proportion of mice (~40%) transplanted with melanoma cells remained free of macroscopic skin lesions long after epicutaneous inoculation, and generation of tumour-specific epidermal CD69+ CD103+ TRM cells correlated with this spontaneous disease control. By contrast, mice deficient in TRM formation were more susceptible to tumour development. Despite being tumour-free at the macroscopic level, mice frequently harboured melanoma cells in the epidermal layer of the skin long after inoculation, and intravital imaging revealed that these cells were dynamically surveyed by TRM cells. Consistent with their role in melanoma surveillance, tumour-specific TRM cells that were generated before melanoma inoculation conferred profound protection from tumour development independently of recirculating T cells. Finally, depletion of TRM cells triggered tumour outgrowth in a proportion (~20%) of mice with occult melanomas, demonstrating that TRM cells can actively suppress cancer progression. Our results show that TRM cells have a fundamental role in the surveillance of subclinical melanomas in the skin by maintaining cancer–immune equilibrium. As such, they provide strong impetus for exploring these cells as targets of future anticancer immunotherapies.

Adoptive Cd8(+) T Cell Therapy Generates Immunological Memory To Inhibit Melanoma Metastasis

Adoptive Transfer of Interleukin-21-stimulated Human CD8(+) T Memory Stem Cells Efficiently Inhibits Tumor Growth

Marked Anti-Tumor Effects of CD8(+)CD62L(+) T Cells from Melanoma-Bearing Mice.

Cancer-associated CD8 + Memory T Cells in the Application of Adoptive Immunotherapy

The cryo-thermal therapy eradicated melanoma in mice by eliciting CD4+ T-cell-mediated antitumor memory immune response

Long-term efficacy of adoptive cell therapy is determined by host CD8+ T cells and undermined by lymphodepleting preconditioning

The characteristics of CD8~+ memory T cell subsets in melanoma mice

Tissue Microenvironment Reprograms the Circulating Memory T Cell Differentiation and Enhances Vaccine-Elicited Anti-Metastasis Immunity

Adoptive Transfer of Tc1 or Tc17 Cells Elicits Antitumor Immunity Against Established Melanoma Through Distinct Mechanisms

Tumor-Specific CD4+ T Cells Restrain Established Metastatic Melanoma by Developing Into Cytotoxic CD4– T Cells

Tissue-resident memory CD8+ T cells promote melanoma–immune equilibrium in skin

Folate-modified Chitosan Nanoparticles Containing the IP-10 Gene Enhance Melanoma-specific Cytotoxic CD8(+)CD28(+) T Lymphocyte Responses

Antigen-specific CD8+ Memory Stem T Cells Generated from Human Peripheral Blood Effectively Eradicate Allogeneic Targets in Mice

Interleukin-7-dependent Expansion and Persistence of Melanoma-Specific T Cells in Lymphodepleted Mice Lead to Tumor Regression and Editing.

Tumor-Specific CD4<SUP>+</SUP> T Cells Restrain Established Metastatic Melanoma by Developing Into Cytotoxic CD4<SUP>-</SUP> T Cells

Adoptive Transfer Of Tumor-Reactive Transforming Growth Factor-Beta-Insensitive Cd8(+) T Cells: Eradication Of Autologous Mouse Prostate Cancer

Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells.

Adoptive transfer of pTRP2-specific CTLs expanding by bead-based artificial antigen-presenting cells mediates anti-melanoma response.

Generation of Pure Highly Functional Human Anti-Tumor Specific Cytotoxic T Lymphocytes With Stem Cell-Like Memory Features for Melanoma Immunotherapy

Human Melanoma Immunotherapy Using Tumor Antigen-Specific T Cells Generated in Humanized Mice

Antitumor Activity from Antigen-Specific CD8 T Cells Generated in Vivo from Genetically Engineered Human Hematopoietic Stem Cells